Benutzer: Gast  Login
Titel:

Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Dokumenttyp:
Journal Article; Article
Autor(en):
Dörr, Jan; Wernecke, Klaus-Dieter; Würfel, Jens; Bellmann-Strobl, Judith; Siffrin, Volker; Sättler, Muriel B; Simons, Mikael; Linsa, Andreas; Tumani, Hayrettin; Paul, Friedemann
Abstract:
Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprotective capacities of the orally available non-opioid and centrally acting analgesic drug flupirtine maleate we hypothesized that treatment with flupirtine maleate might be beneficial in MS patients. Th...     »
Zeitschriftentitel:
Front Neurol
Jahr:
2018
Band / Volume:
9
Seitenangaben Beitrag:
842
Volltext / DOI:
doi:10.3389/fneur.2018.00842
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/30356868
Print-ISSN:
1664-2295
TUM Einrichtung:
Lehrstuhl für Zellbiologie des Nervensystems (Prof. Misgeld)
 BibTeX